List view / Grid view
25 February 2015 | By Ipsen / Canbex Therapeutics Ltd
Ipsen and Canbex Therapeutics Ltd announced that Canbex has granted Ipsen an option giving Ipsen the exclusive right to purchase 100% of Canbex shares upon completion of the Phase IIa study of Canbex’s lead candidate for the treatment of spasticity in people with multiple sclerosis (MS), known as VSN16R...
25 February 2015 | By British Generic Manufacturers Association
The onset of biosimilar competition in the UK in Infliximab is another significant milestone in the development of the sector in this country according to the British Generic Manufacturers Association (BGMA).
24 February 2015 | By Janssen
2015 NHS Innovation Challenge prize winners announced...
24 February 2015 | By UCB
UCB announced that the company’s newly appointed Chief Executive Officer, Jean-Christophe Tellier, has been selected to join the Ministerial Industry Strategy Group...
24 February 2015 | By GBI Research
While drug candidates for Alzheimer’s Disease fail at a much higher rate than the pharmaceutical industry average, the total number of active drugs in the AD treatment pipeline is relatively large at 583, implying a high level of commercial interest, says business intelligence provider GBI Research...
24 February 2015 | By Kuros
Kuros Biosurgery AG, a biotechnology company focused on the development of novel biomaterials and bioactive-biomaterial combination products for sealant, orthobiologic and surgical wound indications, announced that its patent application U.S.S.N 12/102,157 will issue today and has been assigned U.S. Patent No. 8,961,947...
24 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb is to expand its immuno-oncology pipeline with the aquisition of Flexus Biosciences in a deal worth up to $1.25 billion...
24 February 2015 | By Merck KGaA
Merck, in collaboration with Maharashtra University and University of Indonesia, is introducing European Accredited Clinical Diabetes management for more than 5000 medical and pharmacy students of both universities as part of Merck Capacity Advancement Program in Asia...
23 February 2015 | By Eli Lilly & Company
Eli Lilly and Company announced a delay in the submission of basal insulin peglispro (BIL) to regulatory agencies beyond the first quarter of 2015...
23 February 2015 | By Almirall
Almirall, the global pharmaceutical company based in Barcelona, has posted its full-year 2014 results...
23 February 2015 | By Persistence Market Research
North America has the largest market and Asia-Pacific has the fastest growing market for human insulin. In terms of type of human insulin, modern human insulin represents the largest and fastest growing segment of this market...
Eli Lilly and Company (LLY) and Incyte Corporation (INCY) today announce that the investigational medicine baricitinib demonstrated a statistically significant improvement compared to placebo in a second consecutive Phase 3 trial in rheumatoid arthritis (RA). The RA-BUILD study included patients with moderately-to-severely active rheumatoid arthritis who had an inadequate response…
23 February 2015 | By TiGenix NV
TiGenix NV has announced that Dr Julian Panés endorsed the design of the Company's Phase III trial of Cx601 for the treatment of complex perianal fistulas in patients with Crohn's disease during his presentation last week at the 10th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)...
20 February 2015 | By Biotie
Biotie has announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD)...
20 February 2015 | By Genmab
Genmab A/S has entered a co-development and commercialisation agreement with BioNovion to evaluate a number of DuoBody product candidates targeting immune checkpoints...
